NBE-Therapeutics ^Company

NBE-Therapeutics is a Swiss biotech company that was founded in 2012 and acquired by Boehringer Ingelheim in December 2020. The company focuses on developing immune-stimulatory therapies for cancer treatment using its proprietary Antibody-Drug Conjugate platform. NBE-Therapeutics aims to improve the quality of life and increase survival rates for cancer patients worldwide.